Clearmind Medicine Inc.

CMND

$2.36

+$0.06 (2.61%)

Closed

Clearmind Medicine announces grant of new U.S. patent No. 12,357,590 for MEAI-based binge behavior regulators, further strengthening its intellectual property portfolio.

Loading chart...

IndexN/A

Market Cap0.00B

Enterprise Value0.40B

Income$-0.01B

Sales$0.00B

EmployeesN/A

P/E-0.10

P/SN/A

P/B339.13

P/C-85.43

EV/EBITDA-108.21

EV/SalesN/A

EPS (ttm)-24.50

EarningsN/A

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Volume0.06M

Shs Outstand0.00B

Change2.61%

Dividend Est.N/A

Dividend Ex-DateN/A

Perf YTDN/A

Perf YearN/A

Perf 3YN/A

Perf 5YN/A

Perf 10YN/A

IPON/A

Jun 2907:55AMClearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength(globenewswire.com)07:55AMClearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength(globenewswire.com)

Jun 2208:07AMClearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial(globenewswire.com)08:07AMClearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial

Insider Trading

View All

Insider

Type

Price

Value

Date

HRT FINANCIAL LP

Sell

22.1K

$3.31

$73K

Jun 16, 26

HRT FINANCIAL LP

Sell

3.2K

$3.32

$11K

Jun 15, 26

HRT FINANCIAL LP

Sell

2.1K

$3.36

$7K

Jun 12, 26

HRT FINANCIAL LP

Buy

2.2M

$0.15

$330K

Jun 10, 26

Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors. Founded in 2017, the company initially operated under the name Cyntar Ventures Inc. before officially rebranding as Clearmind Medicine Inc. in March 2021. Its operations are headquartered in Vancouver, Canada.

CEO: Adi Zuloff-ShaniEmployees: 4www.clearmindmedicine.com

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	$69.19K	$71.09K	$79.06K	$119.62K	$2.53K	N/A	N/A	N/A
Gross Profit	$-69.19K	$-71.09K	$-79.06K	$-119.62K	$-2.53K	N/A	N/A	N/A
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses	$7.87M	$7.93M	$8.59M	$8.88M	$3.61M	$230.12K	$104.15K	$259.19K
Operating Income	$-7.94M	$-8.00M	$-8.67M	$-9.00M	$-3.61M	$-230.12K	$-104.15K	$-259.19K
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Income	$-5.41M	$-7.31M	$-11.85M	$-9.93M	$-3.66M	$-230.12K	$-104.15K	$-198.09K
Net Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS (Basic)	$-42.53	$-94.38	$-2341.32	$-9164.43	$-4731.05	$-507.60	$-337.61	$-735.01
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Stock Option Compensation Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Price To Earnings Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Price To Sales Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Shares Outstanding	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Market Capitalization	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Clearmind Medicine Inc.

Insider Trading

Discover more